Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.

The Journal of clinical endocrinology and metabolism - 1 Sept 2017

Ooi Teik Chye, Krysa Jacqueline A, Chaker Seham, Abujrad Hussein, Mayne Janice, Henry Kathy, Cousins Marion, Raymond Angela, Favreau Colette, Taljaard Monica, Chrétien Michel, Mbikay Majambu, Proctor Spencer D, Vine Donna F

Abstract excerpt

Context: Proprotein convertase subtilisin kexin 9 (PCSK9) mediates degradation of the low-density lipoprotein receptor (LDLR), thereby increasing plasma low-density lipoprotein cholesterol (LDL-C). Variations in the PCSK9 gene associated with loss of function (LOF) of PCSK9 result in greater expression of hepatic LDLR, lower concentrations of LDL-C, and protection from cardiovascular disease (CVD)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoproteins B
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fasting

Share to Lipoproteins

Share to Ontario

Share to Postprandial Period

Share to Proprotein Convertase 9

Share to Statistics, Nonparametric

Source

Identifiers

PMID: 28673045
DOI: 10.1210/jc.2017-00684

Genes

PCSK9
LDLR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.PMID 28673045Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.Semantic proximity Read ↗

PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial HypobetalipoproteinemiaSemantic proximity Read ↗

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Semantic proximity Read ↗

[PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].Semantic proximity Read ↗

Clinical aspects of PCSK9.Semantic proximity Read ↗

Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.Semantic proximity Read ↗

The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis.Semantic proximity Read ↗

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read ↗

The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.Semantic proximity Read ↗

The PCSK9 decade.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.